Table 4.

Adverse events reported by subjects

Adverse events, n (%)	GLY/eFlow 50 μg (N = 29)	GLY/eFlow 50 μg + Charcoal (N = 29)	GLY/DPI 63 μg (N = 28)	GLY/DPI 63 μg + Charcoal (N = 27)	IV Infusion 50 μg (N = 27)
Any AE	6 (20.7)	9 (31.0)	7 (25.0)	11 (40.7)	7 (25.9)
Ear and labyrinth disorders	1 (3.4)	1 (3.4)	0	0	0
Cerumen impaction	1 (3.4)	0	0	0	0
Ear pain	0	1 (3.4)	0	0	0
Gastrointestinal disorders	1 (3.4)	3 (10.3)	0	3 (11.1)	0
Abdominal discomfort	0	0	0	1 (3.7)	0
Abdominal pain	0	2 (6.9)	0	0	0
Dry mouth	0	0	0	1 (3.7)	0
Nausea	0	1 (3.4)	0	0	0
Toothache	1 (3.4)	0	0	1 (3.7)	0
Vomiting	0	1 (3.4)	0	0	0
General disorders and administration site conditions	1 (3.4)	0	2 (7.1)	2 (7.4)	0
Catheter site hematoma	0	0	0	1 (3.7)	0
Catheter site pain	0	0	1 (3.6)	1 (3.7)	0
Influenza like illness	1 (3.4)	0	0	0	0
Malaise	0	0	0	1 (3.7	0
Vessel puncture site hematoma	0	0	1 (3.6)	0	0
Infections and infestations	0	2 (6.9)	1 (3.6)	0	1 (3.7)
Ear infection	0	0	1 (3.6)	0	0
Gastroenteritis	0	1 (3.4)	0	0	0
Influenza	0	0	0	0	1 (3.7)
Nasopharyngitis	0	1 (3.4)	0	0	0
Musculoskeletal and connective tissue disorders	1 (3.4)	0	2 (7.1)0	1 (3.7)0	0
Back pain	0	0	2 (7.1)	1 (3.7)	0
Musculoskeletal discomfort	1 (3.4)	0	0	0	0
Nervous system disorders	1 (3.4)	4 (13.8)	1 (3.6)	4 (14.8)	4 (14.8)
Headache	1 (3.4)	3 (10.3)	1 (3.6)	4 (14.8)	4 (14.8)
Migraine	0	1 (3.4)	0	0	0
Psychiatric disorders	0	0	0	0	1 (3.7)
Panic attack	0	0	0	0	1 (3.7)
Respiratory, thoracic and mediastinal disorders	1 (3.4)	1 (3.4)	2 (7.1)	1 (3.7)	1 (3.7)
Cough	1 (3.4)	1 (3.4)	0	0	0
Dry throat	0	0	1 (3.6)	0	1 (3.7)
Dyspnea	0	0	0	1 (3.7)	0
Oropharyngeal pain	0	0	1 (3.6)	0	0
Skin and subcutaneous tissue disorders	1 (3.4)	1 (3.4)	0	0	0
Ecchymosis	1 (3.4)	1 (3.4)	0	0	0
Vascular disorders	0	0	0	1 (3.7)	1 (3.7)
Hypertension	0	0	0	1 (3.7)	0
Phlebitis	0	0	0	0	1 (3.7)

AE adverse event, DPI dry powder inhaler, GLY glycopyrronium bromide